Thomas Jefferson University

Jefferson Digital Commons
Department of Biochemistry and Molecular
Biology Faculty Papers

Department of Biochemistry and Molecular
Biology

9-27-2022

Enhanced Membrane Binding of Oncogenic G Protein αqQ209L
qQ209L
Confers Resistance to Inhibitor YM-254890
Clinita E. Randolph
Thomas Jefferson University

Morgan B. Dwyer
Thomas Jefferson University

Jenna L. Aumiller
Thomas Jefferson University

Alethia J. Dixon
Case Western Reserve University School of Medicine

Asuka Inoue

Follow
and additional works at: https://jdc.jefferson.edu/bmpfp
Tohokuthis
University
Part of the Medical Biochemistry Commons

Let
uspage
know
howauthors
access to this document benefits you
See next
for additional
Recommended Citation
Randolph, Clinita E.; Dwyer, Morgan B.; Aumiller, Jenna L.; Dixon, Alethia J.; Inoue, Asuka; Osei-Owusu,
Patrick; and Wedegaertner, Philip B., "Enhanced Membrane Binding of Oncogenic G Protein αqQ209L
Confers Resistance to Inhibitor YM-254890" (2022). Department of Biochemistry and Molecular Biology
Faculty Papers. Paper 228.
https://jdc.jefferson.edu/bmpfp/228

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Biochemistry and Molecular Biology Faculty Papers by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Authors
Clinita E. Randolph, Morgan B. Dwyer, Jenna L. Aumiller, Alethia J. Dixon, Asuka Inoue, Patrick OseiOwusu, and Philip B. Wedegaertner

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/bmpfp/228

RESEARCH ARTICLE

Enhanced membrane binding of oncogenic G protein
αqQ209L confers resistance to inhibitor YM-254890
Received for publication, March 24, 2022, and in revised form, September 15, 2022 Published, Papers in Press, September 27, 2022,
https://doi.org/10.1016/j.jbc.2022.102538

Clinita E. Randolph1,‡, Morgan B. Dwyer1,‡, Jenna L. Aumiller1, Alethia J. Dixon2 , Asuka Inoue3,
Patrick Osei-Owusu2, and Philip B. Wedegaertner1, *
From the 1Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University,
Philadelphia, Pennsylvania, USA; 2Department of Physiology and Biophysics, Case Western Reserve University School of Medicine,
Cleveland, Ohio, USA; 3Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan
Edited by Henrik Dohlman

Heterotrimeric G proteins couple activated G protein–
coupled receptors (GPCRs) to intracellular signaling pathways. They can also function independently of GPCR activation
upon acquiring mutations that prevent GTPase activity and
result in constitutive signaling, as occurs with the αqQ209L
mutation in uveal melanoma. YM-254890 (YM) can inhibit
signaling by both GPCR-activated WT αq and GPCRindependent αqQ209L. Although YM inhibits WT αq by
binding to αq-GDP and preventing GDP/GTP exchange, the
mechanism of YM inhibition of cellular αqQ209L remains to
be fully understood. Here, we show that YM promotes a subcellular redistribution of αqQ209L from the plasma membrane
(PM) to the cytoplasm. To test if this loss of PM localization
could contribute to the mechanism of inhibition of αqQ209L
by YM, we developed and examined N-terminal mutants of
αqQ209L, termed PM-restricted αqQ209L, in which the addition of membrane-binding motifs enhanced PM localization
and prevented YM-promoted redistribution. Treatment of cells
with YM failed to inhibit signaling by these PM-restricted
αqQ209L. Additionally, pull-down experiments demonstrated
that YM promotes similar conformational changes in both
αqQ209L and PM-restricted αqQ209L, resulting in increased
binding to βγ and decreased binding to regulator RGS2, and
effectors p63RhoGEF-DH/PH and phospholipase C-β. GPCRdependent signaling by PM-restricted WT αq is strongly
inhibited by YM, demonstrating that resistance to YM inhibition by membrane-binding mutants is speciﬁc to constitutively
active αqQ209L. Together, these results indicate that changes
in membrane binding impact the ability of YM to inhibit
αqQ209L and suggest that YM contributes to inhibition of
αqQ209L by promoting its relocalization.

Heterotrimeric G proteins, comprised of an α, β, and γ
subunit, act as molecular switches to regulate cell signaling
pathways (1–3). Heterotrimeric G proteins couple to G
protein–coupled receptors (GPCRs), which upon activation
act as guanine-nucleotide exchange factors (GEFs) to
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induce conformational changes that promote GDP release
from the α subunit in exchange for GTP (2, 3). Binding of
GTP to the α subunit results in dissociation of the α subunit from the tightly associated βγ subunit and subsequent
binding of α and βγ to effector proteins. α subunits are
grouped into four families (αs, αi, αq, and α12/13) that
mediate various pathways within the cell (4). The Gαq
family, which is comprised of αq, α11, α14, and α15/16,
classically activate phospholipase Cβ (PLCβ) (5, 6). Active
PLCβ hydrolyzes phosphatidylinositol 4,5-bisphosphate
resulting in production of inositol 1,4,5-trisphosphate and
diacylglycerol (DAG) (7).
αq signaling is essential for physiological processes; however, activating mutations in α subunits can result in dysregulation of signaling and disease. αq and α11, which share
90% identity at the amino acid level and signal similarly, are
mutated mutually exclusively in over 90% of uveal melanoma
cases resulting in their constitutive activity (8–10). α subunits are comprised of a helical domain and a GTPase
domain. The helical domain and GTPase domain form a
crevice where the guanine nucleotide binds (11), and the
GTPase domain contains three critical switch regions (Sw I,
Sw II, and Sw III) that undergo conformational changes
allowing for GTP binding. The switch regions are also
important for intrinsic GTP hydrolysis activity, which is
accelerated by GTPase-activating proteins (GAPs). αq/11
mutations in uveal melanoma most frequently involve a
missense mutation at glutamine 209 to leucine or less
commonly proline. The mutation at glutamine 209 located in
Sw II greatly diminishes the ability of αq or α11 to hydrolyze
GTP rendering them constitutively active (12). The implications of αq mutations in disease warrants an urgent need
to better understand the biology of αq under physiological
and disease conditions.
Two major signaling pathways that are activated by
constitutively active αq to promote cell growth and proliferation are the mitogen-activated protein kinase (MAPK)
pathway and the nuclear translocation of the transcription
coactivators Yes-associated protein 1 (YAP) and paralog
transcriptional coactivator with PDZ-binding motif (TAZ).
MAPK pathway activation occurs via increased DAG
J. Biol. Chem. (2022) 298(11) 102538
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production upon αq activation of the classical effector PLCβ.
DAG then serves a dual role in membrane recruitment of
the RasGEF RasGRP3 and protein kinase C isoforms δ/ε
(PKCδ/ε), which phosphorylate and further activate
RasGRP3 (13, 14). The resulting activation of Ras then
stimulates the well-known MAPK cascade. On the other
hand, activated αq initiates the YAP/TAZ pathway by
directly binding to and activating the RhoGEF Trio (15).
Activation of Rho then leads to focal adhesion kinase
(FAK)–dependent disruption of the cytoplasmic retention of
YAP/TAZ, thereby promoting translocation of YAP/TAZ
into the nucleus (16). Both the MAPK pathway and translocation of YAP into the nucleus promote transcription of
cell growth and proliferative genes, resulting in uveal melanoma progression (13–16).
A number of studies show the promise of YM-254890
(YM) and FR900359 (FR) as inhibitors of WT and constitutively active αq/11 (17–21). YM and FR are naturally
occurring cyclic depsipeptides isolated from Chromobacterium and Ardisia crenata, respectively. Both compounds,
having highly similar structures (22), are thought to have
similar mechanisms of action of preventing the release of
GDP from αq and thereby preventing activation by inhibiting the exchange of GDP for GTP (19, 21, 23). Although it is
clear that FR/YM can effectively inhibit constitutive
αqQ209L signaling, αqQ209L is thought to exist predominantly in the GTP-bound form due to the lack of GTP hydrolysis activity, presenting a paradox as to how FR/YM can
trap αqQ209L in the GDP-bound form (24). Thus, the
mechanisms of how constitutively active αqQ209L is regulated in cells and how FR/YM inhibit αqQ209L remain to be
fully understood.
Importantly, membrane localization is critical for signaling
by both WT and constitutively active αq. αq gains afﬁnity for
the plasma membrane (PM) through interaction with βγ (25,
26), palmitoylation at cysteines 9 and 10 (27), and an N-terminal polybasic motif (28). PM localization is particularly
important for interaction with the GPCR and effector proteins
such as PLCβ. Furthermore, mutational disruption of these
membrane-targeting mechanisms of WT and constitutively
active αq results in cytoplasmic localization and attenuation of
signaling, demonstrating that PM localization is critical for αq
signaling (25–29). Moreover, α subunits can trafﬁc reversibly
between the PM and intracellular organelles, highlighting the
importance of subcellular localization for G protein signaling
function (29, 30). Understanding further how localization
regulates signaling by constitutively active αq is critical for
gaining new insight into ways to inhibit dysregulated αq
signaling.
In our studies, we provide evidence that YM treatment results in the redistribution of αqQ209L from the PM to the
cytoplasm. Additionally, we generated PM-restricted αqQ209L
mutants that displayed resistance to inhibition of signaling by
YM. These studies suggest the importance of YM-induced
translocation of αqQ209L into the cytoplasm as an additional way in which YM inhibits constitutively active αq.
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Results
YM promotes the redistribution of αqQ209L from the PM to
cytoplasm
While studying the effect of YM-254890 (YM) on αqdependent signaling, we observed surprisingly that YM promoted a change in localization of αqQ209L and to a lesser
extent αq WT. Immunoﬂuorescence microscopy of HEK
293 cells stably expressing tetracycline-inducible αqQ209L
showed that treatment of cells with 1 μM YM for 1 h promoted a redistribution of αqQ209L from a PM localization to
an intracellular localization (Fig. 1A). Scoring αqQ209L
localization in individual cells as PM localized, PM and cytoplasmic, or cytoplasmic showed that in dimethyl sulfoxide
(DMSO) vehicle-treated cells, αqQ209L displayed a predominant PM localization in 63% of cells, colocalizing at the PM
with GRK5, a protein shown to strongly localize at the PM
when expressed in HEK 293 cells (31), and a distribution to
both the PM and cytoplasm in 25% of cells (Fig. 1, A and B).
However, after 1 h of YM treatment, only 5% of cells showed
strong PM localization of αqQ209L; instead, αqQ209L was not
detected at the PM and was localized in the cytoplasm in 84%
of cells. Redistribution of αqQ209L was also observed after
24 h of YM treatment, but more PM localization remained
compared to 1 h YM treatment (Fig. 1, A and B). Although
αqQ209L displays a decrease in PM localization after YM
treatment, GRK5 remains strongly localized at the PM, indicating that the observed redistribution of αqQ209L is not
simply due to a general disruption in PM localization of peripheral membrane-bound proteins. In HEK 293 cells stably
expressing tetracycline-inducible αq WT, a small but consistent shift-off of the PM for αq WT was observed after YM
treatment (Fig. 1, A and B), but only αqQ209L displayed a
dramatic redistribution. Translocation of αqQ209L in
response to YM was also observed in HeLa cells (Fig. S1).
To begin to address whether the observed YM-promoted
redistribution of αqQ209L is related to the ability of YM to
inhibit constitutive signaling by αqQ209L, we examined a time
course of YM inhibition. αqQ209L activates the MAPK
pathway through its canonical signaling pathway mediated by
PLCβ. Immunoblotting of cell lysates with a phospho-ERK
(pERK)–speciﬁc antibody was used as a read out of MAPK
signaling. In cells expressing αqQ209L, a signiﬁcant decrease
in pERK levels was detected after 1 h of YM treatment. pERK
continued to decrease at 2 to 3 h and remained inhibited up to
16 h after YM treatment (Fig. 1C). These experiments together
show that the YM-promoted redistribution of αqQ209L appears to precede YM-induced inhibition of signaling, raising
the question of whether YM-promoted loss of PM localization
of αqQ209L plays a role in the ability of YM to inhibit
constitutive signaling by αqQ209L.
YM does not disrupt the PM localization or signaling of SrcαqQ209L or Lyn-αqQ209L
If redistribution from the PM plays a role in YM inhibition
of αqQ209L signaling, we reasoned that a mutant of αqQ209L
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Figure 1. YM promotes dissociation of αqQ209L from the PM. A, Flp-In HEK 293 cells were transfected with GRK5-mCherry and treated with tetracycline
to induce expression of αq and αqQ209L. The tetracycline-induced αq- and αqQ209L-Flp-In HEK 293 cells were treated with DMSO or 1 μM YM for 1 h or
overnight. αq, αqQ209L, and GRK5 were visualized by immunoﬂuorescence microscopy, as described under Experimental procedures. The scale bars
represent 10 μM. B, the localization of αq- or αqQ209L in 100 tetracycline-induced Flp-In HEK 293 cells in each of n = 3 experiments were scored as either
PM localized with little to no observable staining in the cytoplasm, PM, and cytoplasmic localization in which individual cells displayed varying degrees of a
partial PM stain and observable cytoplasmic localization of αq or cytoplasmic in which αq was distributed throughout the cytoplasm but had no observable
PM localization. Statistical signiﬁcance comparing experimental conditions was determined as described under Experimental procedures. Results are shown
as mean ± SD (n = 3; experiments *p <0.05, two-way ANOVA, Fisher’s Least Signiﬁcant Differences test). C, expression of αqQ209L was tetracycline induced
in Flp-In HEK 293 cells, and cells were treated with 1 μM YM for the indicated times. Cell lysates were immunoblotted using antibodies for the indicated
proteins. pERK and ERK signal intensities were quantiﬁed and normalized to pERK/ERK signal intensity in DMSO treatment. Results are shown as mean ± SD
(n = 3; *p <0.05; **p <0.01, one-way ANOVA, Dunnett’s multiple comparisons test). DMSO, dimethyl sulfoxide; PM, plasma membrane.

that remains at the PM upon YM treatment would continue
to signal in the presence of YM. To test this idea, we initially
constructed mutants of αqQ209L in which additional PMtargeting motifs were added to the N terminus to augment
the ability of reversible palmitoylation at cysteines 9 and 10 to
maintain PM localization. Amino acids 1 to 16 of Src or
amino acids 1 to 11 of Lyn were fused to the N terminus of
αqQ209L to introduce a myristoylation plus polybasic motif
and a myristoylation plus palmitoylation motif, respectively
(Fig. 2A). The addition of a similar N-terminal sequence of
Src has been shown to strongly localize αs at the PM and
prevent activation-induced subcellular redistribution of αs

(32). Immunoﬂuorescence microscopy showed that SrcαqQ209L or Lyn-αqQ209L displayed strong PM localization
and colocalization with GRK5, when expressed in HEK 293 q/
11 KO cells in which αq and α11 were knocked out using
CRISPR (Fig. 2B). Importantly, Src-αqQ209L and LynαqQ209L remained at the PM after YM treatment (Fig. 2B),
thus demonstrating that the addition of the Src or Lyn motif
is sufﬁcient to prevent YM-promoted redistribution of
αqQ209L.
To determine if these PM-restricted αqQ209L mutants are
sensitive to inhibition by YM, we assayed pERK levels −/+ YM
treatment by immunoblot analysis. Expression of αqQ209L,
J. Biol. Chem. (2022) 298(11) 102538
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Figure 2. Src- and Lyn-αqQ209L remain at the PM upon YM treatment and are resistant to inhibition by YM. A, schematic of αqQ209L, Src-αqQ209L,
and Lyn-αqQ209L, indicating sites of palmitoylation (P), myristoylation (M), and a polybasic motif (++++). B, Src-αqQ209L or Lyn-αqQ209L was cotransfected
with GRK5-mCherry in HEK 293 q/11 K/O cells and cells were treated with DMSO or 1 μM YM for 1 h. Src-αqQ209L, Lyn-αqQ209L, and GRK5-mCherry were
visualized by immunoﬂuorescence microscopy. The scale bars represent 10 μM. C, HEK 293 q/11 K/O cells were transfected with αq-pcDNA3, αqQ209LpcDNA3, Src-αqQ209L-pcDNA3, Lyn-αqQ209L-pcDNA3, or pcDNA3 vector alone and treated with DMSO or 1 μM YM overnight. Cell lysates were immunoblotted using antibodies for the indicated proteins. pERK and ERK signal intensities were quantiﬁed and normalized to pERK/ERK signal intensity in DMSO
treatment in pcDNA3-transfected cells. D and E, HEK 293 q/11 K/O cells were transfected with αq-pcDNA3, αqQ209L-pcDNA3, Src-αqQ209L-pcDNA3, LynαqQ209L-pcDNA3, or pcDNA3 alone, along with renilla luciferase and either pSRE luciferase (D) or 8xGTIIC (TEAD) luciferase (E). Cell lysates were prepared,
and luciferase assays were performed and quantitated as described under Experimental procedures. Cell lysates were immunoblotted using antibodies for
the indicated proteins. In (C–E) results are shown as mean ± SD (n = 4 in C, n = 3 in D and E; *p <0.05; **p <0.01; ***p <0.001, two-way ANOVA, Sidák’s
multiple comparisons test). DMSO, dimethyl sulfoxide.

4 J. Biol. Chem. (2022) 298(11) 102538

Localization-dependent inhibition of αqQ209L by YM-254890

Figure 3. αq-AGQ209 L remains at the PM upon YM treatment and is resistant to YM inhibition. A, schematic of αq, αqAG, and αqAGQ209L. B, αqAGQ209L was cotransfected with GRK5-mCherry in HEK 293 q/11 K/O cells, and cells were treated with DMSO or 1 μM YM for 1 h. αqAG-Q209L and GRK5mCherry were visualized by immunoﬂuorescence microscopy. The scale bars represent 10 μM. C, HEK 293 q/11 K/O cells were transfected with αq-pcDNA3,
αqQ209L-pcDNA3, αqAG-Q209L, or pcDNA3 vector alone and treated with DMSO or 1 μM YM overnight. Cell lysates were immunoblotted using antibodies
for the indicated proteins. pERK and ERK signal intensities were quantiﬁed and normalized to pERK/ERK signal intensity in DMSO treatment in αq-transfected cells. D and E, HEK 293 q/11 K/O cells were transfected with αq-pcDNA3, αqAG-pcDNA3, αqQ209L-pcDNA3, αqAG-Q209L-pcDNA3, or pcDNA3 alone,
along with renilla luciferase and either pSRE luciferase (D) or 8xGTIIC (TEAD) luciferase (E). Cell lysates were prepared, and luciferase assays were performed
and quantitated as described under Experimental procedures. Cell lysates were immunoblotted using antibodies for the indicated proteins. In (C–E) results
are shown as mean ± SD (n = 3: *p <0.05; **p <0.01, two-way ANOVA, Sidák’s multiple comparisons test). DMSO, dimethyl sulfoxide; PM, plasma membrane.

Src-αqQ209L, or Lyn-αqQ209L in HEK 293 q/11 KO cells
resulted in similar constitutive activation of pERK, approximately 5-fold higher than in vector transfected or αq WT

expressing cells (Fig. 2C). While YM treatment abolished
αqQ209L activation of pERK, Src-αqQ209L- and LynαqQ209L-dependent activation of pERK was strongly resistant
J. Biol. Chem. (2022) 298(11) 102538
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to inhibition by YM. These results provide the ﬁrst evidence
that signaling by PM-restricted forms of αqQ209L is not
effectively inhibited by YM.
To examine further this insensitivity to YM of PM-restricted
αqQ209L, we utilized two transcriptional reporter assays. The
serum response element (SRE) luciferase reporter assay detects
αq-dependent signaling via both MAPK- and Rho-dependent
pathways, and the TEAD luciferase reporter assay detects
αq-dependent signaling via Rho-dependent translocation into
the nucleus of the transcription coactivator YAP. Consistent
with the pERK assay (Fig. 2C), expression of αqQ209L, SrcαqQ209L, or Lyn-αqQ209L in HEK 293 q/11 KO cells resulted
in similar constitutive activation of SRE-luciferase and TEADluciferase signals (Fig. 2, D and E). However, and again
consistent with the pERK assays, YM treatment resulted in
little or no inhibition of signaling by Src-αqQ209L or LynαqQ209L, even though αqQ209L signaling was abolished after
YM treatment. Taken together, these results demonstrate that
the addition of N-terminal PM-targeting motifs to αqQ209L
does not affect constitutive signaling but does confer resistance to YM.
Myristoylated αqAG-Q209L remains localized to the PM and is
resistant to YM
To further determine if signaling by PM-restricted αqQ209L
fails to be inhibited by YM, we took advantage of a previously
described N-terminal, membrane-binding mutant of αq. In
this AG mutant, the ﬁrst methionine codon is mutated so that
αq utilizes the methionine codon at position 7 as the initiating
ATG, and the alanine at position 8, now position 2 in the AG
mutant, is changed to a glycine codon to introduce a new site
for myristoylation (25). Thus, the αqAG-Q209L mutant is
singly myristoylated and dually palmitoylated, in contrast to
only dual palmitoylation for αqQ209L, thereby providing an
additional lipid modiﬁcation to increase PM localization
(Fig. 3A). Consequently, immunoﬂuorescence microscopy
showed that αqAG-Q209L localized at the PM, colocalizing
with GRK5 (Fig. 3B), and αqAG-Q209L remained at the PM
after YM treatment (Fig. 3B). Thus, the simple introduction of
a site for N-terminal myristoylation is sufﬁcient to prevent
YM-promoted redistribution of αqAG-Q209L, similar to that
observed for the more complex Src-αqQ209L or LynαqQ209L mutants (Fig. 2, A and B).
To determine if αqAG-Q209L signaling, like Src-αqQ209L
and Lyn-αqQ209L signaling, was also insensitive to YM
inhibition, we ﬁrst examined pERK levels stimulated by
αqAG-Q209L and the effect of YM treatment. Expression of
αqAG-Q209L in HEK 293 q/11 KO cells resulted in strong
constitutive activation of the MAPK pathway, as revealed by
pERK immunoblotting, similar to αqQ209L (Fig. 3C). However, the constitutive pERK activation by αqAG-Q209L was
resistant to YM treatment. Upon YM treatment, αqQ209L
signaling to pERK was signiﬁcantly reduced but αqAG-Q209L
retained its pERK signaling. We also used SRE and TEAD
luciferase reporter assays to further conﬁrm αqAG-Q209L’s
lack of inhibition of by YM (Fig. 3, D and E). Expression of
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either αqQ209L or αqAG-Q209L in HEK 293 q/11 KO cells
resulted in strong constitutive activation in both luciferase
transcriptional reporter assays. However, overnight YM
treatment failed to inhibit SRE-dependent and TEADdependent luciferase activity in cells expressing αqAGQ209L, even though YM treatment completely blocked
signaling by αqQ209L. Collectively, our results demonstrate
that enhanced membrane binding, displayed by three different
PM-restricted αqQ209L mutants, prevents relocalization and
inhibition by YM, supporting the idea that YM-induced subcellular redistribution of αqQ209L is important for inhibition
of signaling by YM.
YM insensitivity of PM-restricted αqAG-Q209L is not due to
expression level or YM concentration
To address concerns that the aforementioned demonstrations of resistance to YM are artefacts of high levels of αqAGQ209L expression or inappropriate concentrations of YM, we
performed key control experiments. First, we assessed TEADdependent transcription using decreasing amounts of expression of αqQ209L and αqAG-Q209L. αqQ209L displayed a
strong and signiﬁcant decrease in TEAD luciferase activity
upon YM treatment at both high and low expression levels
(Fig. 4A). However, αqAGQ209L signaling remained resistant
to YM at all expression levels, indicating that lack of inhibition
by YM observed for this PM-restricted mutant was not due to
high levels of expression. Second, we analyzed YM concentration curve. Using concentrations from 10 nM to 5 μM, we
observed the expected YM concentration-dependent inhibition of αqQ209L signaling with an approximate IC50 of 9 nM,
as measured here by TEAD luciferase activity. However,
αqAG-Q209L signaling remained resistant to YM inhibition at
all concentrations, including 5 μM YM (Fig. 4B). Additionally,
we performed TEAD luciferase assays in HEK 293 cells, rather
than the HEK 293 q/11 KO cells that lack endogenous αq and
α11 (Fig. 4C). Signaling by expressed αqAG-Q209L in HEK
293 cells remained resistant to YM inhibition, indicating that
this failure to be inhibited by YM occurs for PM-restricted
αqAG-Q209L regardless of the presence or absence of
endogenous WT αq and α11. Taken together, these results
demonstrate that insensitivity to YM of PM-restricted
αqAGQ209L is maintained at various expression levels of
αqAG-Q209L, various concentrations of YM, and in HEK 293
parental cells.
YM affects αqQ209L and PM-restricted αqAG-Q209L similarly
in regulating binding to regulators and effectors
We next tested whether YM was binding to the PMrestricted mutants by assaying the ability of added YM to
affect the interaction of αqAG-Q209L with several binding
partners. Previous work showed that addition of YM to cells
expressing αqQ209L promoted increased interaction with Gβγ
and decreased interaction with regulator of G protein signaling
2 (RGS2), consistent with a proposed mechanism of YM
binding to αqQ209L and shifting it into an inactive form (19).
Here, we expressed αqQ209L and αqAG-Q209L, as well as the
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Figure 4. The resistance of PM-restricted αqQ209L mutants to YM occurs independently of protein expression level, YM concentration, or
presence of endogenous αq/11. A, HEK 293 q/11 K/O cells were transfected with renilla luciferase, 8xGTIIC luciferase, and increasing amounts of
αqQ209L or αqAGQ209L, as indicated. Cells were treated with 1 μM YM
overnight. Cell lysates were prepared, and luciferase assays were performed
and quantitated as described. Cell lysates were also immunoblotted using
antibodies for the indicated proteins. B, HEK 293 q/11 K/O cells were
transfected with renilla luciferase, 8xGTIIC luciferase, and αqQ209L or
αqAGQ209L. Cells were treated with increasing concentrations of YM
overnight. Lysates were prepared, and luciferase assays were performed
and quantitated. C, αqQ209L or αqAG-Q209L were cotransfected with renilla
luciferase and 8xGTIIC luciferase in HEK 293 cells then treated with DMSO or
YM overnight. Lysates were prepared, and luciferase assays were performed
and quantitated. Cell lysates were also immunoblotted using antibodies for
the indicated proteins. In (A and C) results are shown as mean ± SD (n = 3;
*p <0.05; **p <0.01; ***p <0.001, two-way ANOVA, Sidák’s multiple comparisons test). DMSO, dimethyl sulfoxide.

WT forms of αq and αqAG, in HEK 293 cells stably expressing
poly-His-tagged β1. Previous work has demonstrated that Gβγ
associates with αqQ209L similarly to its association with WT
αq; the mechanism of such strong interaction of αqQ209L
with Gβγ remains to be fully understood (26, 33). To observe
the association of expressed αq subunits with Gβγ, we used
nickel nitrilotriacetic acid (Ni-NTA) magnetic agarose beads
to pull down poly-His-β1 from cell lysates and then immunoblotted for αq. These βγ pull-down assays showed that YM
treatment promoted a similar increased interaction of both
αqQ209L and αqAGQ209L with Gβγ upon YM treatment
(Fig. 5A). Additionally, both WT αq and αqAG showed an
expected increase in association with Gβγ upon YM treatment.
We also interrogated the ability of αqAG-Q209L to interact
with RGS2 and the effect of YM. RGS2 binds to GTP-bound
forms of αq and acts as a GTPase-activating protein (GAP)
to stimulate the hydrolysis of GTP. Although the Q209L
mutation greatly reduces αq’s intrinsic and RGS2-stimulated
GTPase activity, αqQ209L is still able to associate with RGS2
(19). However, GDP-bound αq displays a poor afﬁnity for
RGS2, and therefore, reduced association of Q209L mutants
with RGS2 in response to YM treatment would be consistent
with YM binding and inducing an inactive conformation. To
test this, we performed a GST-RGS2 pull-down assay, in which
puriﬁed GST-RGS2, immobilized on GSH sepharose beads,
was incubated with cell lysates containing the expressed αq
subunits (Fig. 5B). The pull-down results showed that both
αqQ209L and αqAG-Q209L displayed a signiﬁcant and similar
reduction in association with RGS2 after treating the cells with
YM.
Similarly, binding to key effector proteins was examined.
GST pull downs were performed with the extended PH/DH
domain of p63RhoGEF, a direct effector of αq that stimulates
activation of RhoA and downstream signaling (34). In addition,
coimmunoprecipitation experiments were performed after
coexpression of PLCβ-3 with αqQ209L or αqAG-Q209L (35).
In both assays, αqQ209L and αqAG-Q209L were coisolated
with the protein domain or effector protein at a similar level
(Fig. 5, C and D). Consistent with the GST-RGS2 pull downs
(Fig. 5B), treatment with YM reduced the level of αqQ209L or
αqAG-Q209L that interacted with GST-p63RhoGEF-DH/
PHext or PLCβ-3. Pull-down and immunoprecipitation experiments provide an important approach for monitoring
changes in protein–protein interactions in response to YM;
however, we note that protein–protein interactions detected in
a cell lysate may not fully reﬂect the situation in the intact cell.
Collectively, these results indicate that although YM fails to
inhibit signaling mediated by PM-restricted αqAG-Q209L, YM
is able to bind to and promote an inactive conformation of
αqAG-Q209L.
Signaling by GPCR-activated αqAG is sensitive to YM
We next wanted to determine if GPCR-dependent signaling
by WT PM-restricted αq is also refractory to inhibition by YM.
To test this, we transfected αq or αqAG into HEK 293 q/11
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Figure 5. PM-restricted αqQ209L displays YM-induced conformational changes. A, HEK 293 cells stably expressing His-Myc-β1γ2 were transfected with
αq-pcDNA3, αqAG-pcDNA3, αqQ209L-pcDNA3, αqAG-Q209L-pcDNA3, or pcDNA3 vector alone then treated with 1 μM YM overnight. A βγ pull-down assay
was done after the overnight YM treatment. Pull-down and whole cell lysates were immunoblotted using antibodies for the indicated proteins. αq signal
intensities in the pull down were quantiﬁed and normalized to their respective signal intensities in untreated (-YM) cells to quantify the increase in association with β1γ2 after YM treatment. B, HEK 293 q/11 K/O cells were transfected with αq-pcDNA3, αqAG-pcDNA3, αqQ209L-pcDNA3, αqAG-Q209LpcDNA3, or pcDNA3 vector alone then treated with 1 μM YM overnight. A GST-RGS2 pull-down assay was done after the overnight YM treatment. Pull-down
and whole cell lysates were immunoblotted using antibodies for the indicated proteins, and GST-RGS2 in the pull down was visualized with Ponceau S
staining. αqQ209L and αqAG-Q209L signal intensities in the pulldown were quantiﬁed and normalized to their respective signal intensities in untreated cells
to quantify the decrease in association with RGS2 after YM treatment. C, HEK 293 q/11 K/O cells were transfected and treated with 1 μM YM as in B, and a
GST-p63RhoGEF-DH/PHext pull-down assay was performed. Proteins were visualized and quantitation performed as in (B). D, HEK 293 q/11 K/O cells were
transfected with αqQ209L-pcDNA3, αqAG-Q209L-pcDNA3, or pcDNA3 together with pcDNA3.1-FLAG-PLCβ-3 where indicated. FLAG-PLCβ-3 was immunoprecipitated from cell lysates as described under Experimental Procedures. Immunoprecipitates and cell lysates were immunoblotted using antibodies for
the indicated proteins. The asterisk in the PLCβ-3 IP panel indicates a nonspeciﬁc band. Immunoprecipitated αqQ209L and αqAG-Q209L signal intensities
were divided by the corresponding PLCβ-3 signal and then normalized to the respective signal intensities in the untreated sample. Results are shown as
mean ± SD (n = 3; *p < 0.05, **p < 0.01, Student’s t test). PM, plasma membrane.
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KO cells and then activated the endogenous muscarinic
acetylcholine m3 receptor (m3AChR) with 100 μM carbachol
in the presence or absence of pretreatment with YM for 2 h
prior to carbachol treatment. Both αq and αqAG were able to
activate the MAPK pathway within 5 min of carbachol treatment as assessed by immunoblotting for pERK (Fig. 6A).
Importantly, treatment with YM abolished carbachol stimulation of the MAPK pathway for both αq or αqAG, indicating
that signaling by GPCR-activated αqAG, in contrast to

constitutive signaling by αqAG-Q209L, is fully inhibited by
YM. To further assess the sensitivity of GPCR-activated αqAG
to YM, we used the SRE luciferase reporter and TEAD luciferase reporter assays. Overnight treatment with carbachol
resulted in robust stimulation of SRE luciferase and TEAD
luciferase activity via either αq and αqAG (Fig. 6B), and similar
to the results with pERK (Fig. 6A), both αq- and αqAGmediated signaling was completely blocked by the addition of
YM. Taken together, our results show that the surprising

Figure 6. GPCR-activated αqAG is sensitive to YM. A, HEK 293 q/11 K/O cells were transfected with αq or αqAG, then treated with 100 μM carbachol for 5,
15, or 30 min after 2 h pretreatment with 1 μM YM or DMSO vehicle control. Cell lysates were immunoblotted using antibodies for the indicated proteins
and pERK/ERK signal intensities were quantiﬁed. Results are shown as mean ± SD (n = 3; **p <0.01; ***p <0.001, two-way ANOVA, Dunnett’s multiple
comparisons test). B and C, HEK 293 q/11 K/O cells were transfected with αq-pcDNA3, αqQ209L-pcDNA3, αqAG-Q209L, or pcDNA3 alone, along with
muscarinic acetylcholine m3 receptor, renilla luciferase, and either pSRE luciferase (B) or 8xGTIIC (TEAD) luciferase (C). Cells were then treated with 100 μM
carbachol overnight after a 1 h pretreatment with 1 μM YM or DMSO vehicle control. αq Q209L and αqAG-Q209L were treated with either 1 μM YM or
DMSO vehicle control overnight. Luciferase assays were performed and quantitated as described previously. Cell lysates were immunoblotted using antibodies for the indicated proteins. Results are shown as mean ± SD (n = 3; **p <0.01; ***p <0.001, two-way ANOVA, Sidák’s multiple comparisons test).
DMSO, dimethyl sulfoxide; GPCE, G protein–coupled receptor.
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ability of PM-restricted αq to resist inhibition by YM is unique
to the constitutively active Q209L mutants; GPCR-activated
signaling by PM-restricted αq retains sensitivity to YM.

Discussion
The studies presented here suggest a novel mechanism for
inhibition of constitutively active αqQ209L by the depsipeptide
YM-254890 (YM). It is well accepted that YM and the very
similar FR900359 (FR) inhibit GPCR activation of αq by
locking αq in the GDP-bound state (17, 21, 23). In addition to
inhibiting classical GPCR activation of αq, recent work has
shown that YM can inhibit signaling and cell proliferation
driven by αqQ209L (18–20). However, constitutively active
αqQ209L is assumed to exist in a GTP-bound active state due
to its lack of GTPase activity, and thus an understanding of
how YM could similarly trap constitutively active αqQ209L in
an inactive state has remained a challenge. Results herein
address this challenge by supporting an additional mechanism
for YM inhibition of αqQ209L. The key ﬁndings are that (1)
YM promotes subcellular redistribution of αqQ209L off of the
PM and (2) YM fails to inhibit signaling by PM-restricted
mutants of αqQ209L. Our results propose a model in which
YM binding promotes the dissociation of αqQ209L from the
PM, and the resulting decreased PM localization prevents
αqQ209L signaling.
Our studies have revealed an unexpected subcellular redistribution of αqQ209L in response to YM treatment. Importantly, previous work on the trafﬁcking of Gα subunits has led
to a model in which Gα can reversibly shuttle between the PM
and internal membranes in both constitutive and activationdependent manners (29, 30, 36–39). Although it is clear that
G proteins can trafﬁc to different locations in the cell, a
detailed mechanistic understanding remains to be deﬁned. The
main insight into a mechanism is that changes in palmitoylation and depalmitoylation of Gα can play a key role in their
trafﬁcking (29, 40). In this regard, it was reported that αq fused
to a photoconvertible ﬂuorescent protein could rapidly shuttle
between the PM and intracellular membranes and also
that blocking palmitoylation of αq by treatment with
2-bromopalmitate or depletion of speciﬁc palmitoyl acyltransferases led to loss of PM localization of αq (29). Thus, an
attractive model for our observation of YM-promoted redistribution of αqQ209L is that binding of YM by αqQ209L leads
to changes in its palmitoylation status. However, in initial
studies, we have not been able to demonstrate consistent
changes in palmitoylation of αq or αqQ209L when cells are
treated with YM. Moreover, our studies so far have not been
able to conclusively determine the subcellular localization of
αqQ209L upon translocation from the PM. After YM treatment, αqQ209L appears diffusely localized throughout the cell
with no clear colocalization with intracellular organelles.
Intriguingly, cellular fractionation experiments show a small
shift of αqQ209L into a soluble, cytosolic fraction after YM
treatment, consistent with a potential mechanism of depalmitoylation (Fig. S2). Future studies will be needed to understand the mechanism of this YM-promoted redistribution of
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αqQ209L; it is currently unclear whether YM binding by
αqQ209L stimulates retrograde movement off of the PM or
inhibits anterograde trafﬁcking for return to the PM. To our
knowledge, results reported herein are the ﬁrst demonstration
of a small molecule binding to a heterotrimeric G protein
subunit that affects its subcellular localization. YM is likely to
provide an important tool to help unravel trafﬁcking mechanisms of Gα.
The most compelling ﬁndings in our studies were that
simply adding additional membrane binding motifs to the N
terminus of αqQ209L were sufﬁcient to prevent YM from
inhibiting signaling by these mutant αqQ209L. Palmitoylation
at cysteines 9 and 10 is essential for PM localization and
signaling of WT and constitutively active mutants of αq, and
cycles of enzymatic palmitoylation and depalmitoylation can
control the subcellular distribution of αq proteins. We
reasoned that appending additional membrane binding motifs
to αqQ209L would result in a stronger attachment to the PM,
and indeed N-terminal fusion of a myristoylation + basic
sequence from Src, a myristoylation + palmitoylation sequence
from Lyn, or the simple AG mutation to introduce a site of
myristoylation resulted in PM-restricted mutants of αqQ209L
that were predominantly localized at the PM and remained at
the PM upon YM treatment. Signaling by Src-αqQ209L, LynαqQ209L, and αqAG-Q209L failed to be inhibited by YM.
Moreover, we demonstrated that insensitivity to YM was
maintained at different concentrations of YM and different
expression levels of αqAG-Q209L (Fig. 4, A and B). A previous
study reported an IC50 of 12 nM YM for inhibiting signaling
by αqQ209L (41), consistent with the YM concentration curve
in our studies (Fig. 4B). Nonetheless, concentrations of up to
5 μM YM still failed to inhibit αqAG-Q209L. Increasing
expression of αqQ209L led to increased signaling, and YM
fully inhibited signaling by αqQ209L at all levels of expression;
however, YM was unable to inhibit αqAG-Q209L signaling at
any level of expression (Fig. 4A). Taken together, the failure of
YM to inhibit the PM-restricted forms of αqQ209L supports a
model in which translocation off of the PM contributes to the
mechanism of YM inhibition of αqQ209L.
The surprising resistance to YM of PM-restricted mutants
was speciﬁc to the constitutively active αqQ209L. In our
studies, both WT αq and WT αqAG efﬁciently and similarly
coupled carbachol-stimulated endogenous m3AChR or
expressed m3AchR to activation of ERK and stimulation of
luciferase readouts, respectively. However, in these assays,
signaling by both WT αq and αqAG were able to be
completely inhibited by YM. This sensitivity to YM of GPCRstimulated signaling by αqAG was in contrast to our demonstrations that signaling by αqAG-Q209L was insensitive to
YM. These results are consistent with the proposal that there
are key mechanistic differences in cells regarding how WT αq
versus GTPase-deﬁcient αq mutants are inhibited by YM.
A key question that we addressed was whether PMrestricted αqAG-Q209L is capable of binding YM. Importantly, although our experiments showed that signaling by
PM-restricted αqAG-Q209L is insensitive to YM, our studies
determined that YM is still able to bind PM-restricted
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αqAG-Q209L and promote conformational changes similar to
those that occur upon YM binding by αqQ209L. Based on a
crystal structure of YM bound to WT αq and biochemical
studies with YM or the highly similar FR900359, the accepted
mechanism of action is that YM binds to GDP-bound WT αq
and thereby locks it in the inactive state (19, 21, 23). Moreover,
cell-based studies have indicated that FR900359 binding can
also promote a conformation in αqQ209L, consistent with it
being in an inactive, GDP-bound form (18, 19). Our studies
used pull-down experiments to show that αqQ209L displayed
increased association with Gβγ and decreased association with
RGS2, p63RhoGEF-DH/PHext, and PLCβ after treatment of
cells with YM (Fig. 5), showing that YM can promote an
inactive conformation of αqQ209L, consistent with similar
reported experiments using FR900359 (19). Critically, αqAGQ209L showed the same YM-dependent changes of interaction with these binding partners as did αqQ209L. Thus, the
failure of YM to inhibit signaling by αqAG-Q209L cannot be
ascribed to an inability of αqAG-Q209L to bind YM.
How then does signaling by PM-restricted αqQ209L mutants avoid inhibition by YM? Taken together, our results
suggest a model in which YM-promoted subcellular redistribution of αqQ209L contributes to the mechanism of inhibition, in addition to the already recognized potential of YM to
shift αq subunits into an inactive conformation. In this model,
YM binding induces translocation of αqQ209L off of the PM;
the redistributed αqQ209L is then unable to stimulate effector
proteins and signaling pathways. This is supported by reports
showing that αq and constitutively active mutants of αq
completely lack signaling function when PM localization is
disrupted (25–29). PM-restricted αqQ209L mutants, on the
other hand, remain associated with the PM in the presence of
YM and thus continue to signal, even if bound to YM.
Furthermore, our results showing that YM promotes a similar
conformation in both αqQ209L and αqAG-Q209L raises the
possibility that YM binding to constitutively active αqQ209L
and the apparent resulting inactivating conformational change,
may not be sufﬁcient for inhibition by YM. Because αqQ209L
lacks GTPase activity, it is assumed that a substantial proportion of αqQ209L exist in the active, GTP-bound form in
cells; however, it is also assumed that YM binds to an inactive,
GDP-bound form of αqQ209L, and thus it remains to be fully
understood how YM could rapidly lock enough αqQ209L in a
GDP-bound form to fully inhibit signaling. It is worthwhile to
note a recent study of constitutively active αsR201C (42). The
authors demonstrated that GDP-bound αsR201C can exist in
an active conformation capable of activating the effector adenylyl cyclase, contrary to assumptions that αsR201C would be
inactive when bound to GDP. Thus, the results of Hu and
Shokat raise the possibility that YM binding to αqQ209L and
the resulting shift to a GDP form, may not be sufﬁcient to
generate an inactive αqQ209L; additional mechanisms, such as
subcellular redistribution, may be necessary. Further support
for our model is our demonstration that GPCR-stimulated
signaling via WT αq or WT αqAG is efﬁciently inhibited by
YM treatment. These WT αq are likely to be predominantly in
the GDP-bound inactive form when YM is added to cells,

allowing YM to rapidly lock them in an inactive form. Thus,
additional mechanisms of YM action are likely not required for
inhibition of WT αq, highlighting the uniqueness of constitutively active αqQ209L.
An additional model to explain the insensitivity of PMrestricted αqQ209L mutants is that the addition of N-terminal membrane-binding motifs affects the ability of αqQ209L to
bind key regulatory proteins that may help mediate the
inhibitory effect of YM on αqQ209L. For example, as of yet
unidentiﬁed proteins may facilitate the inhibitory effect of YM
by mediating relocalization of αqQ209L, but such proteins
may not effectively interact with PM-restricted αqQ209L.
Likewise, other proteins may prevent the inhibitory effect of
YM by maintaining signaling function of PM-restricted
αqQ209L. In this regard, a recent report argued that the
proportion of αqQ209L already bound to the effector PLCβ
would be refractory to inhibition by FR, an inhibitor almost
identical to YM; because αqQ209L would not be susceptible to
the GTPase accelerating protein (GAP) activity of PLCβ, the
αqQ209L-PLCβ complex would be longer lived than an αqPLCβ complex and consequently inaccessible to the inhibitor
FR or YM (20). In this model, we can speculate that a PMrestricted αqQ209L, with tighter membrane binding than
αqQ209L, may exist in a membrane-bound complex with
PLCβ and other proteins that is more difﬁcult to disrupt and
thus less able to be inhibited by YM. However, in contrast to
this idea, our immunoprecipitation studies failed to show any
increase in association of αqAG-Q209L with PLCβ-3
compared to αqQ209L association with PLCβ-3 (Fig. 5D).
Nonetheless, we cannot rule out that in the intact cell αqAGQ209L, compared to αqQ209L, is more strongly associated
with PLCβ-3 or other interacting proteins. Future studies to
identify novel proteins that regulate inhibition of αqQ209L
and structural studies to understand how YM and/or GDP
binding affects αqQ209L are needed to more fully understand
YM inhibition of constitutively active αq mutants.
In summary, our studies show that YM promotes a change
in localization of αqQ209L from the PM to cytoplasm and that
restricting αqQ209L to the PM results in a loss of inhibition by
YM, suggesting that this change in localization is important for
YM’s mechanism of action. The mutation of Q209L in αq or
the highly identical α11, is the major oncogenic driver mutation in uveal melanoma. A deeper understanding of how the
depsipeptide inhibitor YM inhibits αqQ209L will guide the
development of new inhibitors and potentially reveal new
therapeutic targets.

Experimental procedures
Reagents, antibodies, and plasmids
YM-254890 (catalog no.: # 257-00631) was purchased from
Wako Chemicals USA Inc. DMSO (catalog no.: # BP231-1)
was purchased from Fisher. HEK 293 cells and HEK293 αq/
11 K/O cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (Corning, catalog no.: # 10-017-CV) containing 10%
fetal bovine serum (Gemini, catalog no.: 900-108) and 1×
penicillin/streptomycin solution (Sigma, catalog no.: # P4333).
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All other cell culture plates and materials were from GenClone, Costar, or Fisher. Lipofectamine 2000 (catalog no.: #
11668-019), used for all transient transfections, was obtained
from Invitrogen. Ponceau S (catalog no.: # P-3504) and
carbachol were obtained from Sigma–Aldrich.
The following primary antibodies were used. The GAPDH
(catalog no.: # 60004-1-Ig) and αq (catalog no.: #13927-1-AP)
antibodies were purchased from ProteinTech. This αq antibody (catalog no.: #13927-1-AP) was used for all immunoﬂuorescence microscopy experiments together with a GRK4-6,
clone A16/17 (catalog no.: #05-466) antibody, which was obtained from Sigma–Aldrich. An additional αq antibody (catalog no.: # ab199533) was purchased from Abcam and was used
for all immunoblotting experiments. The HSP90 antibody
(catalog no.: # sc-7947) was obtained from Santa Cruz
Biotechnology. The pERK1/2 (catalog no.: #9101S) and ERK1/
2 (catalog no.: #4696S) antibodies were obtained from Cell
Signaling Technologies. The anti-myc tag antibody, clone 9E1
(catalog no.: # 05-419) was obtained from Sigma–Aldrich. For
immunoﬂuorescence microscopy, the secondary goat antirabbit Alexa Fluor 488 (catalog no.: # A-11034) and goat
antimouse Alexa Fluor 594 (catalog no.: # A-11032) conjugated secondary antibodies were obtained from Invitrogen.
The secondary LI-COR antibodies, IRDye 800CW donkey
antimouse IgG (H + L) (catalog no.: # 92532212), and IRDye
680RD goat anti-rabbit IgG (H + L) (catalog no.: #92568071)
were purchased from LI-COR and were used to visualize
protein on immunoblots. Alternatively for immunoblotting,
horseradish peroxidase-conjugated secondary antibodies (catalog no.: # PR-W4011 and PR-W4021) were used from
Promega.
HA-tagged αq, αqQ209L, αqAG, and αqAGQ209L in
pcDNA3 were described previously (25–27). Nontagged human αq (catalog no.: # GNA0Q00000) and αqQ209L (catalog
no.: # GNA0Q000C0) in pcDNA3.1 were received from the
complementary DNA Resource Center. Src-αqQ209L and
Lyn-αqQ209L in pcDNA3 were generated using synthetic
DNA (GenScript) and subcloning into HA-tagged αqQ209LpcDNA3 and resulted in coding sequences for amino acids 1 to
16 of Src and 1 to 11 of Lyn, respectively, followed by DNA
coding for the linker Gly-Thr-Gly-Gly-Ser-Gly-Gly-Gly-SerGly-Gly-Gly-Ser-Gly-Ala and then fusion to Thr2 of
αqQ209L. pmCherry(N1)-GRK5, in which mCherry is fused to
the C terminus of GRK5 was described previously (31), and the
bacteria expression plasmid for GST-RGS2 has been described
(43, 44). A bacteria expression plasmid for GST-p63RhoGEFDH/PHext and pcDNA3.1-FLAG-PLCβ-3 were generously
provided by Mikel Garcia-Marcos (Boston University).
Cell lines
HEK 293 cells were received from ATCC. HEK 293
q/11 K/O cells have been described (17). HEK 293 cells stably
expressing myc-His-tagged β1 and γ2 were described previously (26). The cells were maintained in HEK293 cell media
plus 0.5 mg/ml G418. For generation of HEK 293 cells
expressing tetracycline-induced αq and αqQ209L, HEK
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293 cells stably expressing an integrated Flp Recombination
Target (FRT) site and Tet repressor (TR) (Flp-In T-REx HEK
293 cells) were received from Diane Merry (Jefferson) and
were cultured in HEK 293 media plus 15 μg/ml blasticidin and
100 μg/ml zeocin. HA-tagged αq and αqQ209L complementary DNA in a pcDNA3 vector backbone were cut using the
restriction endonucleases Hind III and Apa I and ligated into
the pcDNA5/FRT/TO expression vector, which contained a
hybrid human cytomegalovirus (CMV)/TetO2 promotor for
tetracycline-regulated expression of αq or αqQ209L, FRT site
for Flp recombinase–mediated integration of the vector into
the Flp-In T-REx HEK 293 cells, and a hygromycin resistance
gene for selection. The HEK 293 cells were transfected with
2 μg of HA-tagged αq-pcDNA5/FRT/TO or αqQ209LpcDNA5/FRT/TO plus 13 μg of POGG44 ﬂip recombinase.
HEK 293 cells with integrated αq or αqQ209L were selected by
using HEK 293 media plus 15 μg/ml blasticidin and 100 μg/ml
hygromycin and single colonies were expanded under blasticidin and hygromycin selection. αq and αqQ209L Flp-In
T-REx HEK293 cell clones were validated by observation of
equal expression across cells by immunoﬂuorescence upon
100 nM tetracycline treatment and nuclear YAP and increased
pERK upon tetracycline treatment in αqQ209L Flp-In T-REx
HEK 293 cells.
Immunoﬂuorescence microscopy
Immunoﬂuorescence microscopy experiments involved
coexpression of αq or αqQ209L and GRK5-mCherry-N1,
which localizes at the PM and does not interact with αq
(31, 45). αq and αqQ209L Flp-In T-REx HEK 293 cells were
initially transfected with GRK5-mCherry-N1 before tetracycline treatment then reseeded onto 6-well plates with coverslips 24 h after transfection. About 100 ng/ml tetracycline was
then used to induce expression of αq and αqQ209L. The cells
were then treated with DMSO or 1 μM YM in DMSO overnight or for 1 h prior to ﬁxing. To detect localization of SrcαqQ209L or Lyn-αqQ209L HEK 293 q/11 K/O cells were
seeded onto poly-L-lysine-coated coverslips and transfected
with Src-αqQ209L or Lyn-αqQ209L plus GRK5-mCherry-N1.
Forty-eight hours after transfection, the cells were treated with
YM for 1 h then ﬁxed. All cells were ﬁxed with 3.7% formaldehyde in PBS for 15 min, then washed three times with PBS.
The cells were then blocked and permeabilized by incubation
with 2.5% milk and 1% Triton X-100 in tris-buffered saline
(TBS) for 20 min. Coverslips were then incubated with an antirabbit αq antibody and antimouse GRK 4 to 6 antibody in 2.5%
milk and 1% Triton X-100 in TBS for 1 h. The cells were then
washed ﬁve times in 2.5% milk and 1% Triton X-100 in TBS
then incubated with goat anti-rabbit Alexa Fluor 488 and goat
antimouse Alexa Fluor 594 secondary antibodies in 1% Triton
X-100 in TBS for 30 min. After ﬁve washes in 1% Triton X-100
in TBS, the cells were rinsed in distilled water and mounted
onto glass slides with ProLong Diamond Anti-fade Mountant
(Invitrogen, catalog no.: # P36970). Images were acquired on
an Olympus IX83 microscope with a 60× oil immersion
objective and an ORCA Fusion sCMOS camera (Hamamatsu)
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controlled by cellSense (Olympus software). Images were
subjected to constrained iterative deconvolution to remove
background ﬂuorescence. Hundred tetracycline-induced αq
and αqQ209L Flp-In HEK 293 cells under each treatment were
counted and scored as either PM localized with little to no
observable staining in the cytoplasm, PM, and cytoplasmic
localization in which individual cells displayed varying degrees
of a partial PM stain and observable cytoplasmic localization of
αq or cytoplasmic in which αq was distributed throughout the
cytoplasm but had no observable PM localization.

buffer with 1% β-mercaptoethanol were added to the Ni-NTA
beads and the whole cell lysates. The pull down and input were
separated by SDS-PAGE, transferred onto nitrocellulose
membrane, and probed with an αq (Abcam, catalog no.: #
ab199533) or an anti-myc monoclonal antibody (9E10) to
detect β1 or HSP90 antibody as a loading control. The bands
were visualized by chemiluminescence and subjected to
densitometry. Each sample was normalized to its respective
DMSO treatment.
GST-RGS2 and GST-p63RhoGEF-DH/PHext pull-down assays

Dual luciferase assay
HEK 293 αq/11 K/O cells were cotransfected with Renilla
luciferase and either pSRE-luciferase or the synthetic TEAD
reporter 8xGTIIC-luciferase along with the respective αq
construct. 8xGTIIC-luciferase was received from Stefano
Piccolo (Addgene plasmid # 34615) and pSRE-luciferase was
described previously (46). For experiments using constitutively
active mutants, the media was changed to serum-free media
plus 1 μM YM or DMSO vehicle control 2 h after transfection,
then lysed approximately 16 h after transfection. For experiments involving GPCR-activated αq, the cells were treated
with 1 μM YM or DMSO vehicle control 2 h after transfection,
treated with 100 μM carbachol or vehicle control 1 h after
DMSO or YM treatment, and then lysed approximately 16 h
after transfection. The cells were lysed in 1× passive lysis buffer
and luciferase activity was detected using the Dual-Luciferase
Reporter Assay System kit (Promega, catalog no.: # E1960)
according to the manufacturer’s directions, using an opaque
white 96-well plate and GloMax Explorer luminometer.
βγ pull-down assay
The βγ pull-down assay was done as described in (26).
Brieﬂy, HEK 293 cells stably expressing β1γ2 were transiently
transfected with HA-tagged αq-pcDNA3, αqQ209L-pcDNA3,
αqAG-pcDNA3, αqAG-Q209L-pcDNA3, or pcDNA3 alone.
Twenty-four hours after transfection, the cells were treated
with 1 μM YM or DMSO vehicle control overnight. The cells
were then washed in PBS and lysed in 500 μl of lysis buffer C
(20 mM Hepes pH 7.5, 100 mM NaCl, 0.7% Triton X-100,
5 mM MgCl2, and 1 mM EDTA supplemented with the protease inhibitors 1 mM PMSF, 2 μg/ml leupeptin, and 2 μg/ml
aprotinin, and 0.1× cOmplete mini protease inhibitor cocktail).
The lysates were incubated for 1 h on ice then centrifuged at
13,000 rpm (10,000g) for 3 min to pellet the nuclei and
insoluble material. Forty microliters of the supernatant was
reserved for the input, and 20 μl of Ni-NTA magnetic beads
(New England Biolabs, catalog no.: #S1423S) were added to a
new tube with the remaining supernatant. The tubes were
rotated e-o-e for 2 h at 4  C. The beads were then pelleted by
centrifugation for 1 min, then the supernatant was aspirated
while the beads were pelleted on a magnetic rack. The beads
were washed three times in lysis buffer C to remove nonspeciﬁc proteins. Fifty microliters of elution buffer (0.25 M
imidazole in lysis buffer C) was added to each sample to elute
poly-His β1 and any associated proteins. SDS-PAGE sample

The GST-RGS2 and GST-p63RhoGEF-DH/PHext pulldown assays was performed as described in (35, 43). Brieﬂy,
GST-RGS2 and GST-p63RhoGEF-DH/PHext was expressed in
BL-21 cells and BL-21(DE3) cells, respectively. GST-RGS2
expression was induced with 0.5 mM IPTG for 3 h at 25  C
and GST-p63RhoGEF-DH/PHext was induced with 1 mM
IPTG overnight at 18  C. The GST fusion proteins were then
puriﬁed using GSH-Sepharose 4B beads (GE Healthcare, catalog no.: # 17-0765-01) as described (35, 44). HEK 293 q/11 K/O
cells were transfected with pcDNA3, HA-tagged αq-pcDNA3
or αqQ209L-pcDNA3, or αqAG-Q209L-pcDNA3. Twenty-four
hours after transfection, the cells were treated with 1 μM YM or
DMSO vehicle control overnight. The cells were then washed
with cold PBS and lysed in 300 μl of lysis buffer (20 mM Tris–
HCl, pH 7.4, 1 mM EDTA, 1 mM DTT, 100 nM NaCl, 5 mM
MgCl2, 0.7% Triton X-100, 1 mM PMSF, and 5 μg/ml leupeptin and aprotinin). The cells were lysed on ice for 1 h, then
centrifuged for 3 min at full speed to pellet the nuclei and
insoluble material. About 50 μl of the supernatant was reserved
for the input and the remaining supernatant was added to a
new tube with 8 μg of GST-RGS2 or GST-p63RhoGEF-DH/
PHext prebound to GSH Sepharose beads and rotated e-o-e
at 4  C for 1 h. After incubation with GST-RGS2 or GSTp63RhoGEF-DH/PHext, the samples were pelleted at
13,000 rpm (10,000g) for 1 min, the ﬂow through was removed
and the beads were washed three times in lysis buffer. The
proteins were eluted from the beads in 50 μl of SDS sample
buffer plus 1% β-mercaptoethanol and the protein was separated by SDS-PAGE and transferred onto nitrocellulose membrane then probed with an antibody detecting αq (Abcam) or
HSP90 as a loading control. GST-RGS2 and GST-p63RhoGEFDH/PHext were detected by staining the membrane with
Ponceau S. The bands were visualized using LI-COR secondary
antibodies and subjected to densitometry. Each sample was
normalized to its respective DMSO treatment.
PLCβ-3 immunoprecipitation
Experiments were performed similarly to a recent report
(35). HEK 293 q/11 KO cells were transiently transfected with
FLAG-tagged PLCβ-3 and αqQ209L-pcDNA3 or αqAGQ209L-pcDNA3. FLAG-tagged PLCβ-3 alone and pcDNA3
alone were transfected as positive and negative controls,
respectively. Three hours after transfection, media was
changed and respective plates were treated with 1 μM YM
overnight. The cells were washed with cold PBS and lysed in
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500 μl of lysis buffer C (20 mM Hepes pH 7.5, 100 mM NaCl,
0.7% Triton X-100, 5 mM MgCl2, and 1 mM EDTA supplemented with 1 mM DTT, 1 mM PMSF, 2 μg/ml leupeptin, and
2 μg/ml aprotinin, and 0.1× cOmplete mini protease inhibitor
cocktail). Lysates were incubated for 30 min on ice and then
centrifuged at 13,000 rpm for 10 min. Fifty microliters of the
supernatant was reserved for the input, while the remaining
supernatant was added to a new tube containing 40 μl of
EZview Red ANTI-FLAG M2 Afﬁnity Gel bead slurry
(Sigma––Aldrich, catalog no.: # F2426). Lysates and beads
were rotated e-o-e for 2 h at 4  C. The beads were then pelleted by centrifugation for 1 min. Supernatant was removed,
and the beads were washed three times with lysis buffer C.
Protein was eluted from the beads in 60 μl of 1× SDS sample
buffer plus 1% β-mercaptoethanol. Pull-down and input
samples were run on 10% SDS-PAGE gels, transferred onto
nitrocellulose membrane, and probed with antibodies detecting PLCβ-3 (Sigma–Aldrich ANTI-FLAG M2, catalog no.: #
F1804), αq (ProteinTech, catalog no.: #13927-1-AP), and
GAPDH as a loading control. The bands were visualized using
LI-COR secondary antibodies and subjected to densitometry.
Coimmunoprecipitated αq was normalized to the amount of
PLCβ-3 detected in the immunoprecipitate.
pERK/ERK analysis
Protein lysates were run on 10% SDS-PAGE gels then
transferred onto nitrocellulose membranes. The membranes
were then probed for with a rabbit polyclonal pERK antibody
(catalog no.: # 9101S) or a mouse monoclonal ERK antibody
(catalog no.: #4696S). A duplicate membrane was probed with
an antibody detecting αq (Abcam) or GAPDH. LI-COR secondary antibodies were used to visualize the protein bands.
The pERK and ERK bands were subjected to densitometry and
the signal obtained from the pERK bands were divided by the
signal detected from ERK. All signals were normalized to 0 h
YM treatment to normalize between experiments.
Western blotting and quantiﬁcation
All protein lysates were run on 10% SDS-PAGE gels and
transferred onto nitrocellulose, blocked in 2.5% bovine serum
albumin (BSA) or 5% milk in TBS plus 0.05% Tween (TBSTween), incubated with primary antibodies overnight in 2.5%
BSA or 5% milk in TBS-Tween, washed three times in TBSTween, incubated with secondary antibodies in 2.5% BSA or
5% milk in TBS-Tween for 1 h, and washed three times in
TBS-Tween. Membranes blotted with LI-COR secondary antibodies were then washed once in PBS then visualized on a LICOR Odyssey. Membranes blotted with horseradish
peroxidase–conjugated secondary antibodies were incubated
with SuperSignal West Dura Extended Duration Substrate
(catalog no.: # 34075) from Thermo Scientiﬁc Dura then
imaged on an Amersham Imager 680 (GE Healthcare).

comparison’s testing was used to calculate signiﬁcance. Multiple comparison testing was performed using Tukey’s test
when all groups were compared with all other groups, and a
Dunnett’s test was used when all groups were compared with a

single control group. Sidák’s
test was performed when DMSO
versus YM treatments were compared as opposed to Tukey’s
test, which was used to compare all groups with all other
groups. The Fisher’s least signiﬁcant differences test was used
for the cell count comparison in Figures 1B and S1 and the cell
fractionation in Fig. S2 to compare all groups without correcting for multiple comparisons. t tests were used in Figure 5
to compare to DMSO treatments set at 1. In all experiments,
error bars indicate mean ± SD with signiﬁcant differences
indicated as *, p < 0.05; **p < 0.01; ***p < 0.001.

Data availability
All data is contained within the paper.
Supporting information—This
information.
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